GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shuttle Pharmaceuticals Holdings Inc (NAS:SHPH) » Definitions » Intrinsic Value: Projected FCF

Shuttle Pharmaceuticals Holdings (Shuttle Pharmaceuticals Holdings) Intrinsic Value: Projected FCF : $0.00 (As of Jun. 08, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Shuttle Pharmaceuticals Holdings Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-06-08), Shuttle Pharmaceuticals Holdings's Intrinsic Value: Projected FCF is $0.00. The stock price of Shuttle Pharmaceuticals Holdings is $0.465. Therefore, Shuttle Pharmaceuticals Holdings's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Shuttle Pharmaceuticals Holdings's Intrinsic Value: Projected FCF or its related term are showing as below:

SHPH's Price-to-Projected-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.575
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Shuttle Pharmaceuticals Holdings Intrinsic Value: Projected FCF Historical Data

The historical data trend for Shuttle Pharmaceuticals Holdings's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shuttle Pharmaceuticals Holdings Intrinsic Value: Projected FCF Chart

Shuttle Pharmaceuticals Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
- - - -

Shuttle Pharmaceuticals Holdings Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Shuttle Pharmaceuticals Holdings's Intrinsic Value: Projected FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Shuttle Pharmaceuticals Holdings's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shuttle Pharmaceuticals Holdings's Price-to-Projected-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shuttle Pharmaceuticals Holdings's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Shuttle Pharmaceuticals Holdings's Price-to-Projected-FCF falls into.



Shuttle Pharmaceuticals Holdings Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Shuttle Pharmaceuticals Holdings  (NAS:SHPH) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Shuttle Pharmaceuticals Holdings's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.465/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shuttle Pharmaceuticals Holdings Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Shuttle Pharmaceuticals Holdings's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Shuttle Pharmaceuticals Holdings (Shuttle Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
One Research Court, Suite 450, Rockville, MD, USA, 20850
Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy.
Executives
Milton Brown director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Bette Jacobs director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., 1 RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Peter Dritschilo officer: President and COO SHUTTLE PHARMACEUTICALS HOLDINGS, INC., SUITE 450, ROCKVILLE MD 20850
Anatoly Dritschilo director, 10 percent owner, officer: CEO and Chairman SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Tyvin Rich officer: Chief Medical Officer SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Mira Jung officer: Chief Scientific Officer SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Hoek Michael Vander officer: Chief Financial Officer SHUTTLE PHARMACEUTICALS HOLDINGS, INC., SUITE 450, ROCKVILLE MD 20850
Steven M Richards director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
William Adkins director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Joshua Schafer director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Chris Senanayake director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850